Sokörpe's HydroKleanse™ Alpha Hydroxy Acids (AHA) Facial Cleanser Cream is a powerful skincare product that contains a unique blend of alpha hydroxy acids (AHAs), including glycolic, tartaric, and malic acids. Together, these AHAs work to gently exfoliate and brighten the skin, leaving it looking and feeling smooth and refreshed.

Glycolic acid is one of the most popular AHAs in skincare products, and for good reason. This acid has a small molecular size that allows it to penetrate deep into the skin, where it can work to dissolve dead skin cells and improve skin texture. By using a product like Sokörpe's HydroKleanse™ Alpha Hydroxy Acids (AHA) Facial Cleanser Cream, which contains glycolic acid, users can help to reduce the appearance of fine lines and wrinkles, as well as improve skin tone and texture.

Tartaric acid is another AHA that is included in Sokörpe's HydroKleanse™ Alpha Hydroxy Acids (AHA) Facial Cleanser Cream. This acid is derived from grapes and is known for its ability to help improve skin hydration and reduce the appearance of fine lines and wrinkles. Tartaric acid is also a natural antioxidant, which helps to protect the skin from damage caused by environmental stressors like pollution and UV radiation.

Malic acid is the third AHA included in Sokörpe's HydroKleanse™ Alpha Hydroxy Acids (AHA) Facial Cleanser Cream. This acid is found in fruits like apples and is known for its ability to help improve skin texture and promote cell renewal. By using a product that contains malic acid, users can help to reduce the appearance of age spots and hyperpigmentation, as well as improve skin tone and texture.

Together, the glycolic, tartaric, and malic acids in Sokörpe's HydroKleanse™ Alpha Hydroxy Acids (AHA) Facial Cleanser Cream work to gently exfoliate and brighten the skin, leaving it looking and feeling smooth and refreshed. With regular use, this cream can help to improve the overall health and appearance of the skin, making it an excellent choice for anyone looking to achieve a glowing, youthful complexion.

By Alexander Brosda, CEO Sokörpe Laboratories